Cargando…

合并MET基因变异的非小细胞肺癌治疗研究进展

Mesenchymal-epithelial transition factor (MET) has long been considered as the most crucial and promising driver gene in the occurrence and development of non-small cell lung cancer (NSCLC), except for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ROS oncogene 1 re...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845091/
https://www.ncbi.nlm.nih.gov/pubmed/36617474
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.54
_version_ 1784870813108797440
collection PubMed
description Mesenchymal-epithelial transition factor (MET) has long been considered as the most crucial and promising driver gene in the occurrence and development of non-small cell lung cancer (NSCLC), except for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ROS oncogene 1 receptor tyrosine kinase (ROS1). In recent years, therapeutic drugs targeting MET have been continuously developed and applied in clinical practice. First, the curative effect of NSCLC patients with MET exon 14 skipping mutations has been further improved. In addition, when MET amplification occurs after resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced EGFR-mutant NSCLC, the combination of MET-TKIs and EGFR-TKIs has brought significant survival benefits and many other advances. This article reviews the treatment progress of NSCLC patients with different types of MET variants under different circumstances, which provides reference for the selection of clinical treatment strategies.
format Online
Article
Text
id pubmed-9845091
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-98450912023-01-30 合并MET基因变异的非小细胞肺癌治疗研究进展 Zhongguo Fei Ai Za Zhi 综述 Mesenchymal-epithelial transition factor (MET) has long been considered as the most crucial and promising driver gene in the occurrence and development of non-small cell lung cancer (NSCLC), except for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ROS oncogene 1 receptor tyrosine kinase (ROS1). In recent years, therapeutic drugs targeting MET have been continuously developed and applied in clinical practice. First, the curative effect of NSCLC patients with MET exon 14 skipping mutations has been further improved. In addition, when MET amplification occurs after resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced EGFR-mutant NSCLC, the combination of MET-TKIs and EGFR-TKIs has brought significant survival benefits and many other advances. This article reviews the treatment progress of NSCLC patients with different types of MET variants under different circumstances, which provides reference for the selection of clinical treatment strategies. 中国肺癌杂志编辑部 2022-12-20 /pmc/articles/PMC9845091/ /pubmed/36617474 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.54 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 综述
合并MET基因变异的非小细胞肺癌治疗研究进展
title 合并MET基因变异的非小细胞肺癌治疗研究进展
title_full 合并MET基因变异的非小细胞肺癌治疗研究进展
title_fullStr 合并MET基因变异的非小细胞肺癌治疗研究进展
title_full_unstemmed 合并MET基因变异的非小细胞肺癌治疗研究进展
title_short 合并MET基因变异的非小细胞肺癌治疗研究进展
title_sort 合并met基因变异的非小细胞肺癌治疗研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845091/
https://www.ncbi.nlm.nih.gov/pubmed/36617474
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.54
work_keys_str_mv AT hébìngmetjīyīnbiànyìdefēixiǎoxìbāofèiáizhìliáoyánjiūjìnzhǎn
AT hébìngmetjīyīnbiànyìdefēixiǎoxìbāofèiáizhìliáoyánjiūjìnzhǎn
AT hébìngmetjīyīnbiànyìdefēixiǎoxìbāofèiáizhìliáoyánjiūjìnzhǎn
AT hébìngmetjīyīnbiànyìdefēixiǎoxìbāofèiáizhìliáoyánjiūjìnzhǎn
AT hébìngmetjīyīnbiànyìdefēixiǎoxìbāofèiáizhìliáoyánjiūjìnzhǎn